Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FVD vs HD-MTX-Ara-C in PCNSL
NCT01960192Phase 4Unknown
- Start
- Jun 2012
- Primary completion
- Jun 2016
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fotemustine and teniposide in primary central nervous system lymphoma (PCNSL) (2 arms). Primary endpoint: Progression-free survival at 24 months. Status: unknown.
02
Drugs
fotemustineteniposide
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT01960192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01960192.